Yan Wisnu Prajoko - Staff of the Sub Division of Surgical Oncology at Universitas Diponegoro, Semarang, Indonesia
Sugeng Pramono - General Surgery Resident at Universitas Diponegoro, Semarang, Indonesia
Agung Hartanto - General Surgery Resident at Universitas Diponegoro, Semarang, Indonesia
Mada Aji Prakoso - General Surgery Resident at Universitas Diponegoro, Semarang, Indonesia

Aromatase inhibitors (AI) are commonly used adjuvant therapy drugs for women with hormone receptor-positive postmenopausal breast cancer. Frequently AI associated side effects include severe joint and muscle pain. Aromatase Inhibitor - Associated Musculoskeletal Syndrome (AIMSS) is a condition that primarily affects the hands, wrists, and knees. This study aimed to determine the efficacy of Moringa oleifera extract as an adjuvant when taken with AI to postmenopausal breast cancer patients with ER (+), PR (+), and observed the CPK levels as inflammation indicators. The Functional Assessment of Cancer Therapy-Breast (FACT-B) can assess subjects’ emotional, physical, functional well-being, social, and also the breast cancer subscale. The research sample consisted of ۴۰ postmenopausal cancer patients with ER (+) and PR (+) immunohistochemistry and as outpatients at the Kasuari facility, Dr. Kariadi Semarang, who experienced pain due to the administration of aromatase inhibitors. The results of the changes in CPK and FACT-B scores in the group that received additional therapy with Moringa oleifera extract were obtained in this study. The treatment group showed CPK level of post-test lower than pre-test (۱۰۵.۳۰ ± ۵۰.۱۹ vs. ۸۸.۱۰ ± ۴۸.۲۴, p <۰,۰۰۱). In addition, treatment group showed lower FACT-B score than control group (۸۳.۴۵ ± ۵.۱۱ vs. ۷۵.۲۵ ± ۴.۰۵, p<۰,۰۰۱). Moringa oleifera extract has a strong anti-inflammatory effect especially for patient with post-menopause breast cancer who received ER (+), PR (+), and aromatase inhibitor treatment. Its anti-inflammatory properties will upgrade breast cancer patient’s quality of life, treatment adherence, long period of breast cancer therapy and outcomes.

Breast cancer Aromatase inhibitor AIMSS CPK FACT, B